MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1726 48 mg Cohort Study Extended to Eight Weeks On August 6, 2025, ...

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

A new class of drugs has become a phenomenon. GLP-1 receptor agonists, originally developed to treat type 2 diabetes, are now ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

GLP-1s, injectable drugs that mimic hormones to reduce blood sugar and promote weight loss, have skyrocketed in popularity.

In India, home to 74 million diabetes patients, a range of supplements is being marketed as natural GLP-1 alternatives, but ...

A sweeping analysis of global studies reveals that stopping weight loss drugs, including well-known treatments like Ozempic and Wegovy, often triggers a rapid return of lost pounds.

This occurred as the drug major Emcure Pharmaceuticals presented bioequivalence study report along with the Phase-III ...

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

Eli Lilly has launched Mounjaro in KwikPen, a prefilled pen for weekly administration, in India to treat type 2 diabetes and ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.